The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Addressing differences in how Black patients with myeloma may present compared to other ethnicities
In this interview, Craig Cole, MD, Karmanos Cancer Institute, Detroit, MI, shares insights into racial and ethnic differences observed in multiple myeloma (MM), highlighting that people of African descent are twice as likely to develop myeloma compared to Caucasians, and have distinct genetic profiles. Dr Cole emphasizes that treatment outcomes for Black patients are comparable or better when treated equally, though historical underrepresentation in clinical trials has led to the delayed recognition of important side effects in this population. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
